Mark Monroe, MD
Family Medicine · Santa Ana, CANPI 1740244532
Payments from drug & device makers
Across 434 payments — averaging $30.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Amgen$1K
- Nestle Healthcare Nutrition Inc.$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- plus $6K from 28 others
What the payments were for
- Food & beverage$13,124100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $1,481 |
| GSK | 39 | $1,297 |
| Amgen(2 entities) | 24 | $1,164 |
| Nestle Healthcare Nutrition Inc. | 53 | $1,132 |
| AstraZeneca | 32 | $1,079 |
| Lilly USA, LLC | 34 | $1,072 |
| Johnson & Johnson | 29 | $964 |
| Aimmune Therapeutics, Inc. | 33 | $881 |
| Merck | 15 | $625 |
| Novo Nordisk | 14 | $555 |
| Novartis | 17 | $392 |
| Pfizer | 12 | $333 |
| Sanofi-aventis U.S. LLC | 16 | $294 |
| Corcept Therapeutics | 5 | $261 |
| Boehringer Ingelheim | 11 | $253 |
| Vifor Pharma, Inc. | 2 | $242 |
| Cvrx, Inc. | 1 | $203 |
| Astellas Pharma US Inc | 7 | $126 |
| Biohaven Pharmaceuticals, Inc. | 1 | $125 |
| Abbott | 4 | $121 |
| Kowa Pharmaceuticals America, Inc. | 5 | $85 |
| Eisai Inc. | 3 | $64 |
| Biogen | 2 | $57 |
| Dexcom, Inc. | 3 | $46 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Gilead | 2 | $35 |
| Boston Scientific | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| CSL Behring | 1 | $18 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,125 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 42 | $63,209 |
| EliquisApixaban | 60 | $49,322 |
| OzempicSemaglutide | 46 | $46,721 |
| XareltoRivaroxaban | 31 | $33,389 |
| FarxigaDapagliflozin Propanediol | 24 | $27,928 |
| JardianceEmpagliflozin | 17 | $21,716 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,021 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $11,591 |
| Clonidine | 84 | $8,778 |
| Nateglinide | 104 | $8,410 |
| Repatha SureclickEvolocumab | 11 | $7,960 |
| JanuviaSitagliptin Phosphate | 14 | $7,156 |
| LinzessLinaclotide | 12 | $6,095 |
| Nebivolol Hcl | 97 | $4,685 |
| Rosuvastatin Calcium | 233 | $4,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $1,072 | $63,20942 claims |
| PfizerEliquis | $333 | $49,32260 claims |
| Novo NordiskOzempic | $555 | $46,72146 claims |
| Johnson & JohnsonXarelto | $964 | $33,38931 claims |
| AstraZenecaFarxiga | $1,079 | $27,92824 claims |
| Boehringer IngelheimJardiance | $253 | $21,71617 claims |
| GSKTrelegy Ellipta | $1,297 | $21,02116 claims |
| AbbVieLinzess, Synthroid | $1,481 | $7,90834 claims |
| MerckJanuvia | $625 | $7,15614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Santa Ana
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.